tradingkey.logo

Park Ha Biological Technology Co Ltd

PHH
0.385USD
0.000
收盤 12/19, 16:00美東報價延遲15分鐘
11.31M總市值
--本益比TTM

Park Ha Biological Technology Co Ltd

0.385
0.000

關於 Park Ha Biological Technology Co Ltd 公司

Park Ha Biological Technology Co Ltd is an investment holding company primarily engaged in developing private skincare label, direct skincare products sales and franchise alliances promotions. The Company mainly operates its business through two segments. The Products Sales segment is engaged in providing skincare and cosmetic products under the brand name Park Ha as well as offering complimentary after-sales beauty services in physical stores. The Franchise Service segment is engaged in entering franchise agreements with its franchisees, pursuant to which the franchisees are granted permission to open and operate a store under the brand name Park Ha or Geni. The Company's products include Little Blue Injection Serum, Parkha Amino Acid Cleansing Foam and other products. The Company mainly conducts its business in domestic market.

Park Ha Biological Technology Co Ltd簡介

公司代碼PHH
公司名稱Park Ha Biological Technology Co Ltd
上市日期Dec 27, 2024
CEOZhang (Xiaoqiu)
員工數量31
證券類型Ordinary Share
年結日Dec 27
公司地址- -
城市- -
上市交易所NASDAQ Capital Market Consolidated
國家- -
郵編- -
電話- -
網址- -
公司代碼PHH
上市日期Dec 27, 2024
CEOZhang (Xiaoqiu)

Park Ha Biological Technology Co Ltd公司高管

名稱
名稱/職務
職務
持股
持股變動
Ms. Xiaoqiu Zhang
Ms. Xiaoqiu Zhang
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Xiaoyan Zhu
Ms. Xiaoyan Zhu
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Xinyu Li
Ms. Xinyu Li
Chief Technology Officer, Product Manager
Chief Technology Officer, Product Manager
--
--
Ms. Li Wang
Ms. Li Wang
Director
Director
--
--
Ms. Yanan Shan
Ms. Yanan Shan
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Qixiong Sheng
Mr. Qixiong Sheng
Independent Director
Independent Director
--
--
Mr. Xiaozhong Yu
Mr. Xiaozhong Yu
Independent Director Nominee
Independent Director Nominee
--
--
名稱
名稱/職務
職務
持股
持股變動
Ms. Xiaoqiu Zhang
Ms. Xiaoqiu Zhang
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Xiaoyan Zhu
Ms. Xiaoyan Zhu
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Xinyu Li
Ms. Xinyu Li
Chief Technology Officer, Product Manager
Chief Technology Officer, Product Manager
--
--
Ms. Li Wang
Ms. Li Wang
Director
Director
--
--
Ms. Yanan Shan
Ms. Yanan Shan
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Qixiong Sheng
Mr. Qixiong Sheng
Independent Director
Independent Director
--
--

收入明細

FY2024
FY2023
FY2022
FY2021
由於公司未披露,未能獲取相關數據
地區USD
名稱
營收
佔比
China (Mainland)
2.38M
0.00%
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Xiaoqiu Holding Ltd
56.24%
Changxin International Ltd Partnership
7.38%
XTX Markets LLC
0.13%
Two Sigma Investments, LP
0.08%
Ground Swell Capital, LLC
0.06%
其他
36.11%
持股股東
持股股東
佔比
Xiaoqiu Holding Ltd
56.24%
Changxin International Ltd Partnership
7.38%
XTX Markets LLC
0.13%
Two Sigma Investments, LP
0.08%
Ground Swell Capital, LLC
0.06%
其他
36.11%
股東類型
持股股東
佔比
Corporation
63.62%
Venture Capital
0.13%
Investment Advisor
0.08%
Hedge Fund
0.08%
Investment Advisor/Hedge Fund
0.05%
Research Firm
0.02%
其他
36.03%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
15
103.15K
0.30%
+40.70K
2025Q2
9
21.62M
81.98%
-25.58K
2025Q1
8
21.60M
81.90%
-29.47K
2024Q4
6
21.63M
82.55%
+21.63M

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Xiaoqiu Holding Ltd
19.05M
56.24%
--
--
Feb 24, 2025
Changxin International Ltd Partnership
2.50M
7.38%
--
--
Feb 24, 2025
Geode Capital Management, L.L.C.
16.85K
0.05%
+69.00
+0.41%
Jun 30, 2025
Morgan Stanley & Co. LLC
7.03K
0.02%
+7.03K
--
Jun 30, 2025
UBS Financial Services, Inc.
1.47K
0%
+1.47K
--
Jun 30, 2025
Morgan Stanley Smith Barney LLC
294.00
0%
+294.00
--
Jun 30, 2025
RBC Capital Markets Wealth Management
19.00
0%
-2.24K
-99.16%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Invesco Golden Dragon China ETF
0%
Invesco Golden Dragon China ETF
佔比0%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Park Ha Biological Technology Co Ltd的前五大股東是誰?

Park Ha Biological Technology Co Ltd的前五大股東如下:
Xiaoqiu Holding Ltd
持有股份:19.05M
佔總股份比例:56.24%。
Changxin International Ltd Partnership
持有股份:2.50M
佔總股份比例:7.38%。
Geode Capital Management, L.L.C.
持有股份:16.85K
佔總股份比例:0.05%。
Morgan Stanley & Co. LLC
持有股份:7.03K
佔總股份比例:0.02%。
UBS Financial Services, Inc.
持有股份:1.47K
佔總股份比例:0.00%。

Park Ha Biological Technology Co Ltd的前三大股東類型是什麼?

Park Ha Biological Technology Co Ltd 的前三大股東類型分別是:
Xiaoqiu Holding Ltd
Changxin International Ltd Partnership
XTX Markets LLC

有多少機構持有Park Ha Biological Technology Co Ltd(PHH)的股份?

截至2025Q3,共有15家機構持有Park Ha Biological Technology Co Ltd的股份,合計持有的股份價值約為103.15K,占公司總股份的0.30% 。與2025Q2相比,機構持股有所增加,增幅為-81.67%。

哪個業務部門對Park Ha Biological Technology Co Ltd的收入貢獻最大?

在FY2024,--業務部門對Park Ha Biological Technology Co Ltd的收入貢獻最大,創收--,占總收入的--% 。
KeyAI